#BGICC2025 #BreastCancer #SERDs #JosephGiligrov #CancerTreatment #OncologyInnovation #Medicine #Health #OneWorldOneFight
January 13, 2025 at 1:02 PM
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
November 17, 2024 at 8:01 PM
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
January 15, 2025 at 1:46 AM
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
In addition to ensuring the safety of your fellow fighters across each battlefield, other factors will also come into play such as terrain modifiers, the special abilities of certain SERDs, and the threat of permanently losing a SERD in battle (uh oh). Certain SERDs can even move after attacking!
July 26, 2025 at 12:11 AM
In addition to ensuring the safety of your fellow fighters across each battlefield, other factors will also come into play such as terrain modifiers, the special abilities of certain SERDs, and the threat of permanently losing a SERD in battle (uh oh). Certain SERDs can even move after attacking!
SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer @hoperugo.bsky.social @ucsfcancer.bsky.social #gotoPER #MBCC25 #bcsm www.onclive.com/view/serds-p...
SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer
Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.
www.onclive.com
March 9, 2025 at 3:55 PM
SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer @hoperugo.bsky.social @ucsfcancer.bsky.social #gotoPER #MBCC25 #bcsm www.onclive.com/view/serds-p...
Hisou Kihei X-Serd (1990) by Masaya and NCS is a sci-fi tactical RPG for the PC Engine in Japan. It is 2384 and Earth is under attack by aliens in powered armor! Enter the SERDs, Earth's own mechanized answer, in a last ditch attempt to retake the planet! (a welcome to Earth thread)
July 26, 2025 at 12:11 AM
Hisou Kihei X-Serd (1990) by Masaya and NCS is a sci-fi tactical RPG for the PC Engine in Japan. It is 2384 and Earth is under attack by aliens in powered armor! Enter the SERDs, Earth's own mechanized answer, in a last ditch attempt to retake the planet! (a welcome to Earth thread)
#Hormone"/hashtag/Hormone" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Hormone im Kampf gegen #Brustkrebs: Neue Wirkstoffe auf Basis von Hormonen versprechen präzisere Therapien bei Brustkrebs. In Teil 5 ihrer Serie über #Hormone"/hashtag/Hormone" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Hormone erklärt @sigridmaerz.bsky.social die neuesten Therapieansätze. #Gesundheit #Krebs
Brustkrebstherapie: Wirkstoffe verbessern Heilungschancen
Innovative Medikamente wie CDK4/6-Hemmer und orale SERDs revolutionieren die Behandlung tückischer Brustkrebsformen. Die Heilungschancen steigen deutlich.
www.riffreporter.de
September 11, 2025 at 5:01 AM
#Hormone"/hashtag/Hormone" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Hormone im Kampf gegen #Brustkrebs: Neue Wirkstoffe auf Basis von Hormonen versprechen präzisere Therapien bei Brustkrebs. In Teil 5 ihrer Serie über #Hormone"/hashtag/Hormone" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Hormone erklärt @sigridmaerz.bsky.social die neuesten Therapieansätze. #Gesundheit #Krebs
Selective Estrogen Receptor Degraders (SERDs) are a novel class of therapies that target and degrade the estrogen receptor, offering an alternative to traditional endocrine therapies in HR+ breast cancer.
January 13, 2025 at 1:02 PM
Selective Estrogen Receptor Degraders (SERDs) are a novel class of therapies that target and degrade the estrogen receptor, offering an alternative to traditional endocrine therapies in HR+ breast cancer.
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
Beyond EMBER-3, novel combinations with SERDs and SERMs also being evaluated with CDK4/6i
Beyond EMBER-3, novel combinations with SERDs and SERMs also being evaluated with CDK4/6i
January 15, 2025 at 1:48 AM
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
Beyond EMBER-3, novel combinations with SERDs and SERMs also being evaluated with CDK4/6i
Beyond EMBER-3, novel combinations with SERDs and SERMs also being evaluated with CDK4/6i
#TumorBoardTuesday
We have not heard any updates from #SABCS24 yet!
📢So join us Tuesday, 01-14-25 at 8PM ET here & on Twitter as @dr-rshatsky.bsky.social & @zoezhang.bsky.social🗣️SERDS & novel Tx for HR+ #breastcancer
RT and bring others into the discussion‼️
We have not heard any updates from #SABCS24 yet!
📢So join us Tuesday, 01-14-25 at 8PM ET here & on Twitter as @dr-rshatsky.bsky.social & @zoezhang.bsky.social🗣️SERDS & novel Tx for HR+ #breastcancer
RT and bring others into the discussion‼️
January 13, 2025 at 7:20 PM
#TumorBoardTuesday
We have not heard any updates from #SABCS24 yet!
📢So join us Tuesday, 01-14-25 at 8PM ET here & on Twitter as @dr-rshatsky.bsky.social & @zoezhang.bsky.social🗣️SERDS & novel Tx for HR+ #breastcancer
RT and bring others into the discussion‼️
We have not heard any updates from #SABCS24 yet!
📢So join us Tuesday, 01-14-25 at 8PM ET here & on Twitter as @dr-rshatsky.bsky.social & @zoezhang.bsky.social🗣️SERDS & novel Tx for HR+ #breastcancer
RT and bring others into the discussion‼️
I still remember when @saratchandarlapaty.bsky.social & team discover ESR1 mutations in breast cancer by painstakingly analyzing patient samples and building lab models. Over a decade later, SERDs like imlunestrant show clear survival benefits in this population.
Follow the science.
#sabcs24
Follow the science.
#sabcs24
The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX
#MedSky #SABCS24
#MedSky #SABCS24
December 12, 2024 at 4:03 AM
I still remember when @saratchandarlapaty.bsky.social & team discover ESR1 mutations in breast cancer by painstakingly analyzing patient samples and building lab models. Over a decade later, SERDs like imlunestrant show clear survival benefits in this population.
Follow the science.
#sabcs24
Follow the science.
#sabcs24
10/20 #TumorBoardTuesday
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
January 15, 2025 at 1:28 AM
10/20 #TumorBoardTuesday
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
🗣️ “The emergence of new SERDs is transforming the treatment landscape, offering more targeted and effective options for HR+ MBC patients,” says Gligorov.
📅 January 23–24, 2025
📍 Hilton Heliopolis Hotel, Cairo, Egypt
🔗 Register now: bgicc.net/forms/regist...
📅 January 23–24, 2025
📍 Hilton Heliopolis Hotel, Cairo, Egypt
🔗 Register now: bgicc.net/forms/regist...
January 13, 2025 at 1:02 PM
🗣️ “The emergence of new SERDs is transforming the treatment landscape, offering more targeted and effective options for HR+ MBC patients,” says Gligorov.
📅 January 23–24, 2025
📍 Hilton Heliopolis Hotel, Cairo, Egypt
🔗 Register now: bgicc.net/forms/regist...
📅 January 23–24, 2025
📍 Hilton Heliopolis Hotel, Cairo, Egypt
🔗 Register now: bgicc.net/forms/regist...
SABCS 2025: A New Framework for Endocrine Therapy in HR+/HER2– Metastatic Breast Cancer
@sabcs.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SABCS #SABCS25 #SABCS2025
@sabcs.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SABCS #SABCS25 #SABCS2025
SABCS 2025: Endocrine Therapy in HR+ MBC
SABCS 2025 highlights major advances in HR-positive metastatic breast cancer endocrine therapy, including oral SERDs, targeted combinations.
oncodaily.com
December 13, 2025 at 1:05 AM
SABCS 2025: A New Framework for Endocrine Therapy in HR+/HER2– Metastatic Breast Cancer
@sabcs.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SABCS #SABCS25 #SABCS2025
@sabcs.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SABCS #SABCS25 #SABCS2025
Ppl think #cancer research is stuck in the '70s, I guess. In addition 2 surgery, #chemo & radiation, there's also:
* Immunotherapy (checkpoint inhibitors, etc.)
* Targeted therapy (antibody drug conjugates, etc.)
* Hormone therapy (AIs, SERMs, SERDs, anti-androgens, etc.)
#CanSky #MedSky
What else?
* Immunotherapy (checkpoint inhibitors, etc.)
* Targeted therapy (antibody drug conjugates, etc.)
* Hormone therapy (AIs, SERMs, SERDs, anti-androgens, etc.)
#CanSky #MedSky
What else?
January 27, 2025 at 7:41 PM
18/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
Beyond SERDs/SERMs…novel endocrine therapies targeting other mechanisms in pipeline:
Proteolysis targeting chimeras (PROTACs), selective ER covalent antagonists, complete ER antagonists just to name a few!🤯
Beyond SERDs/SERMs…novel endocrine therapies targeting other mechanisms in pipeline:
Proteolysis targeting chimeras (PROTACs), selective ER covalent antagonists, complete ER antagonists just to name a few!🤯
January 15, 2025 at 1:50 AM
18/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
Beyond SERDs/SERMs…novel endocrine therapies targeting other mechanisms in pipeline:
Proteolysis targeting chimeras (PROTACs), selective ER covalent antagonists, complete ER antagonists just to name a few!🤯
Beyond SERDs/SERMs…novel endocrine therapies targeting other mechanisms in pipeline:
Proteolysis targeting chimeras (PROTACs), selective ER covalent antagonists, complete ER antagonists just to name a few!🤯
If you enjoy the episode, don’t forget to like, share, and let us know your thoughts in the comments!
#MetastaticBreastCancer #SERDS #NewEpisode #NowStreaming #ListenNow #PodcastCommunity #EpisodeDrop #MustListen #LiveFromStage4 #LIveChat #BCSM
#MetastaticBreastCancer #SERDS #NewEpisode #NowStreaming #ListenNow #PodcastCommunity #EpisodeDrop #MustListen #LiveFromStage4 #LIveChat #BCSM
October 29, 2025 at 4:07 PM
If you enjoy the episode, don’t forget to like, share, and let us know your thoughts in the comments!
#MetastaticBreastCancer #SERDS #NewEpisode #NowStreaming #ListenNow #PodcastCommunity #EpisodeDrop #MustListen #LiveFromStage4 #LIveChat #BCSM
#MetastaticBreastCancer #SERDS #NewEpisode #NowStreaming #ListenNow #PodcastCommunity #EpisodeDrop #MustListen #LiveFromStage4 #LIveChat #BCSM
EMBER-3 data and discussion argue that new oral SERDs are better for ESR1mut because they have better bioavailability/PK than fulvestrant, not novel activity. Important that these tumors clearly are still ER-driven, just need to hit it harder than fulv can in vivo. #SABCS24
December 11, 2024 at 3:40 PM
EMBER-3 data and discussion argue that new oral SERDs are better for ESR1mut because they have better bioavailability/PK than fulvestrant, not novel activity. Important that these tumors clearly are still ER-driven, just need to hit it harder than fulv can in vivo. #SABCS24
Thoughts on this? >> #ASCO25: Arvinas, Pfizer's PROTAC in breast cancer no better
than oral SERDs >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical
than oral SERDs >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical
#ASCO25: Arvinas, Pfizer's PROTAC in breast cancer no better
than oral SERDs
After Pfizer spent $1 billion upfront to license a targeted protein degrader from Arvinas, the latest clinical results suggest that the drug overall is no better than similar pills called SERDs. Arvinas said on Saturday ...
dlvr.it
May 31, 2025 at 1:23 PM
Thoughts on this? >> #ASCO25: Arvinas, Pfizer's PROTAC in breast cancer no better
than oral SERDs >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical
than oral SERDs >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical
New SERDs are showing promise in overcoming resistance to standard treatments, providing hope for better outcomes in metastatic disease.
January 13, 2025 at 1:02 PM
New SERDs are showing promise in overcoming resistance to standard treatments, providing hope for better outcomes in metastatic disease.
13/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 4👩⚕️
Novel, oral SERDs in development w/ ⬆️efficacy ⬇️toxicities
👉💡imlunestrant, studied in the EMBER-3 trial presented at #SABCS24
🔑Pt features:
~37% with ESR1m, ~40% with PIK3CAm, >50% visceral disease
👉1/3 adj ET, 2/3 prior CDK4/6i
👩⚕️Mini Tutorial 4👩⚕️
Novel, oral SERDs in development w/ ⬆️efficacy ⬇️toxicities
👉💡imlunestrant, studied in the EMBER-3 trial presented at #SABCS24
🔑Pt features:
~37% with ESR1m, ~40% with PIK3CAm, >50% visceral disease
👉1/3 adj ET, 2/3 prior CDK4/6i
January 15, 2025 at 1:38 AM
13/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 4👩⚕️
Novel, oral SERDs in development w/ ⬆️efficacy ⬇️toxicities
👉💡imlunestrant, studied in the EMBER-3 trial presented at #SABCS24
🔑Pt features:
~37% with ESR1m, ~40% with PIK3CAm, >50% visceral disease
👉1/3 adj ET, 2/3 prior CDK4/6i
👩⚕️Mini Tutorial 4👩⚕️
Novel, oral SERDs in development w/ ⬆️efficacy ⬇️toxicities
👉💡imlunestrant, studied in the EMBER-3 trial presented at #SABCS24
🔑Pt features:
~37% with ESR1m, ~40% with PIK3CAm, >50% visceral disease
👉1/3 adj ET, 2/3 prior CDK4/6i
🚨 Our new paper is now out in 𝘊𝘢𝘯𝘤𝘦𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩!
ESR1 mutations in ER⁺ breast cancer rewire lipid metabolism, creating a ferroptosis vulnerability 🔬
ACSL4 is a key biomarker & combo with SERDs offers a new strategy.
👏 Congrats to the whole #TBTlab & collaborators!
aacrjournals.org/cancerres/ar...
ESR1 mutations in ER⁺ breast cancer rewire lipid metabolism, creating a ferroptosis vulnerability 🔬
ACSL4 is a key biomarker & combo with SERDs offers a new strategy.
👏 Congrats to the whole #TBTlab & collaborators!
aacrjournals.org/cancerres/ar...
ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Abstract. Endocrine therapy (ET) is the standard of care for estrogen receptor-positive (ER+) breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ES...
aacrjournals.org
November 7, 2025 at 8:20 PM
🚨 Our new paper is now out in 𝘊𝘢𝘯𝘤𝘦𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩!
ESR1 mutations in ER⁺ breast cancer rewire lipid metabolism, creating a ferroptosis vulnerability 🔬
ACSL4 is a key biomarker & combo with SERDs offers a new strategy.
👏 Congrats to the whole #TBTlab & collaborators!
aacrjournals.org/cancerres/ar...
ESR1 mutations in ER⁺ breast cancer rewire lipid metabolism, creating a ferroptosis vulnerability 🔬
ACSL4 is a key biomarker & combo with SERDs offers a new strategy.
👏 Congrats to the whole #TBTlab & collaborators!
aacrjournals.org/cancerres/ar...
15/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 6👩⚕️
Imlunestrant: favorable safety profile vs SoC. Dc rate: 4%
Imlun+abema: diarrhea=most common AE, all grade: 86%, grade≥3: 8%. Dc rate: 6%
No 👁️or 💙AE signals like in other oral SERDS (i.e. photopsia, bradycardia in camizestrant)
👩⚕️Mini Tutorial 6👩⚕️
Imlunestrant: favorable safety profile vs SoC. Dc rate: 4%
Imlun+abema: diarrhea=most common AE, all grade: 86%, grade≥3: 8%. Dc rate: 6%
No 👁️or 💙AE signals like in other oral SERDS (i.e. photopsia, bradycardia in camizestrant)
January 15, 2025 at 1:42 AM
15/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 6👩⚕️
Imlunestrant: favorable safety profile vs SoC. Dc rate: 4%
Imlun+abema: diarrhea=most common AE, all grade: 86%, grade≥3: 8%. Dc rate: 6%
No 👁️or 💙AE signals like in other oral SERDS (i.e. photopsia, bradycardia in camizestrant)
👩⚕️Mini Tutorial 6👩⚕️
Imlunestrant: favorable safety profile vs SoC. Dc rate: 4%
Imlun+abema: diarrhea=most common AE, all grade: 86%, grade≥3: 8%. Dc rate: 6%
No 👁️or 💙AE signals like in other oral SERDS (i.e. photopsia, bradycardia in camizestrant)
I am really excited about research happening with oral SERDs for er+\her2- brain mets - which often feels invisible in the brain mets conversation. #sabcs24
December 13, 2024 at 1:56 PM
I am really excited about research happening with oral SERDs for er+\her2- brain mets - which often feels invisible in the brain mets conversation. #sabcs24